Are the Goals of Therapy Achievable in Patients with Rheumatoid Arthritis Receiving Upadacitinib in Real Clinical Practice?
-
Published:2023-08
Issue:1
Volume:511
Page:180-186
-
ISSN:1607-6729
-
Container-title:Doklady Biochemistry and Biophysics
-
language:en
-
Short-container-title:Dokl Biochem Biophys
Author:
Amirdzhanova V. N.,Karateev A. E.,Pogozheva E. Yu.,Filatova E. S.,Samigullina R. R.,Mazurov V. I.,Anoshenkova O. N.,Lapkina N. A.,Baranov A. A.,Grineva T. Yu.,Lila A. M.,Nasonov E. L.
Abstract
Abstract
The aim of the study was to evaluate the effectiveness of UPA in RA patients in real clinical practice after 3 and 6 months of therapy. The study included 63 RA patients with high activity of the disease. Activity was assessed according to the DAS28(ESR), DAS28(CRP), SDAI, CDAI; functional ability to HAQ; quality of life to the EQ-5D; disease activity according to the patient’s RAPID-3 index; the level of depression and anxiety to the HADS scale. The effectiveness of therapy was evaluated after 3 (n = 45) and 6 (n = 31) months of UPA therapy. Remission or low activity of the disease by 3 months of therapy was achieved by most patients: remission of 69.8% of patients, low activity of the disease—16.3% of patients. Moderate or high activity persisted in 13.9% of patients. By the 6th month of UPA therapy, the number of remissions reached 90%, low activity 3.3%, moderate activity persisted in 6.7% of patients, high activity of the disease was not in any patient. 20% improvement in function was achieved in 71.8% of patients by the 3rd month of therapy and in 77.8% by the 6th month of treatment; the difference in average HAQ values by the 3rd month of therapy was 0.38 points, by the 6th month—0.58 points. After 3 months of follow—up, 31.1% of patients continued taking GC, by 6 months—24.2%. The dose of GC was reduced from an average of 7.23 to 5.6 mg/s. The percentage of patients requiring NSAIDs decreased from 95.2 to 35.6% and 33.3%, respectively. DMARDs continued to be received by 75.6% of patients by 3 months and 69.7% by 6 months of follow-up. Achieving remission or low activity of the disease in patients with RA receiving UPA in real clinical practice is possible in most patients. A rapid decrease in inflammatory activity is accompanied by a significant improvement in the functional state and quality of life of patients. UPA therapy reduces the need for the use of NSAIDs and reduces the dose of GC in a third of patients.
Publisher
Pleiades Publishing Ltd
Subject
General Chemistry,Biochemistry,General Medicine,Biophysics
Reference20 articles.
1. Smolen, J.S., Landewéet, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update, Ann. Rheum. Dis., 2017, vol. 76, pp. 960–977. 2. Taylor, P.C., Moore, A., Vasilescu, R., Alvir, J., and Tarallo, M., A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective, Rheumatol. Int., 2016, vol. 36, pp. 685–695. 3. Baker, K.F. and Isaacs, J.D., Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?, Ann. Rheum. Dis., 2018, vol. 77, no. 2, pp. 175–187. 4. Nasonov, E.L., Aleksandrova, E.N., and Novikov, A.A., Autoimmune rheumatic diseases: results and prospects for researches, Nauchno-Prakt.
Revmatol., 2015, vol. 53, no. 3, pp. 230–237. 5. Nasonov, E.L., Pharmacotherapy for rheumatoid arthritis: new strategy, new targets, Nauchno-Prakt.
Revmatol., 2017, vol. 55, no. 4, pp. 409–419.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|